PPD

OCTOBER 18, 2023

Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030. 1 With this growth comes increased demands for laboratory services at all steps across the development process. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

Alta Sciences

AUGUST 21, 2023

Choosing the Best Bioanalytical Platform for Your Program aasimakopoulos Mon, 08/21/2023 - 20:50 Choosing the right bioanalytical platform for your molecule’s intended use and program segment is crucial to obtaining reliable, robust data in a timely manner. Why Partner With Altasciences for Your Bioanalytical Projects?

Assay Development 52

Assay Development Pharmacokinetics Drug Development Drugs 52

Drug Target Review

OCTOBER 3, 2024

In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development.

Therapies 59

Therapies Engineering Production FDA 59

Elrig

APRIL 29, 2024

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Agency IQ

FEBRUARY 2, 2024

The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. The document has been updated over time to implement advances in understanding cancer and drug development. In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40